Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05519085 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 810
- Enrollment target
- 20
- Study locations
NCT05519085 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by Celgene. The registered enrollment target is 810 participants, above the 261-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05519085, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 810 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Bortezomib
- DRUG mezigdomide
Study Locations (20)
Florida
- Advanced Research - Coral Springs
- Florida Cancer Specialists - South - Fort Myers
- Florida Cancer Specialists - North - St. Petersburg
- Florida Cancer Specialists - East - West Palm Beach
California
- Cancer and Blood Specialty Clinic - Los Alamitos
- Sharp Memorial Hospital - San Diego
- Local Institution - 0273 - West Hollywood
Louisiana
- Our Lady of the Lake RMC - Baton Rouge
- Local Institution - 0255 - New Orleans
- Local Institution - 0385 - Shreveport
Connecticut
- UConn Health - Farmington
- Local Institution - 0208 - New Haven
Georgia
- University Cancer Blood Ctr - Athens
- Local Institution - 0048 - Marietta
Kansas
- Local Institution - 0330 - Garden City
- University of Kansas Medical Center - Westwood
Colorado
- Local Institution - 0381 - Aurora
Maryland
- Sinai Hospital Of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2022-09-20 |
| Est. Completion | 2033-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05519085
The ClinicalTrials.gov registry entry for NCT05519085 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 810 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (210% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT05519085 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05519085 about?
NCT05519085 is a clinical study titled "A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of ther...
What is the current status of trial NCT05519085?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 810 participants. The study started on 2022-09-20. Estimated completion is 2033-11-30.
What conditions does trial NCT05519085 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05519085?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), mezigdomide (DRUG).
Who is sponsoring clinical trial NCT05519085?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05519085 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
ACTIVE NOT RECRUITING · Phase 3
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.